Safety Evaluation of Natural Drugs in Chronic Skeletal Disorders: A Literature Review of Clinical Trials in the Past 20 years

• Published in: Frontiers in pharmacology Vol. 12; p. 801287
• Main Authors: Zhou, Dongyang, Zhang, Hao, Xue, Xu, Tao, Yali, Wang, Sicheng, Ren, Xiaoxiang, Su, Jiacan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 13.01.2022
• Subjects: ageing; chronic skeletal disorders; clinical trial; natural drugs; Pharmacology; safety evaluation; clinical trial; natural drugs; ageing; safety evaluation; chronic skeletal disorders
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2021.801287

Chronic skeletal disorders (CSDs), including degenerative diseases such as osteoporosis (OP) and autoimmune disorders, have become a leading cause of disability in an ageing society, with natural drugs being indispensable therapeutic options. The clinical safety evaluation (CSE) of natural drugs in CSDs has been given priority and has been intensively studied. To provide fundamental evidence for the clinical application of natural drugs in the elderly population, clinical studies of natural drugs in CSDs included in this review were selected from CNKI, Web of Science, PubMed, Science Direct and Google Scholar since 2001. Seventeen randomized controlled trials (RCTs) met our inclusion criteria: four articles were on OP, seven on osteoarthritis (OA), four on rheumatoid arthritis (RA) and two on gout. Common natural drugs used for the treatment of OP include Berberidaceae , Caprifoliaceae root, and Orchidaceae , which have been linked to several mild adverse reactions, such as skin rash, gastric dysfunction, abnormal urine, constipation and irritability. The safety of Araliaceae extract, Burseraceae extract and extract from perna canaliculus was evaluated in OA and upper abdominal pain, and unstable movements were obsrerved as major side effects. Adverse events, including pneumonia, vomiting, diarrhoea and upper respiratory tract infection, were reported when RA was treated with Celastraceae [TwHF] polyglycosides and quercetin ( Brassicaceae ). The present review aimed to summarize the CSE results of natural drugs in CSDs and could provide evidence-based information for clinicians.